Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cavia porcellus dander is a non-standardized allergenic extract derived from the dander of the domesticated guinea pig (*Cavia porcellus*). It is primarily utilized as a diagnostic tool in allergy testing to identify Type I hypersensitivity (allergic sensitization) in patients, particularly those with occupational exposure such as laboratory animal workers, veterinarians, or pet owners. The extract contains a complex mixture of proteins that act as allergens; when administered via skin prick (topical) or intradermal (subcutaneous) injection, these proteins cross-link allergen-specific IgE antibodies bound to the surface of mast cells and basophils. This interaction triggers the release of inflammatory mediators like histamine, resulting in a visible wheal-and-flare reaction at the test site. While its primary use is diagnostic, such extracts are also used in allergen immunotherapy (hyposensitization) to reduce clinical symptoms upon subsequent exposure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cavia porcellus dander.